News
How to Most Effectively Delay Skeletal Events in Patients with Bone Metastases from Solid Tumors?
In a randomized Phase III study, the effectiveness of denosumab and zoledronic acid in preventing skeletal events in patients with multiple myeloma or solid tumors (excluding breast and prostate cancer) and bone metastases was evaluated. An ad hoc analysis of this study then involved only a subgroup of patients with solid tumors.
Effect of Denosumab and Zoledronic Acid on Overall Survival in Patients with Metastatic Lung Cancer
In 30-40% of patients with non-small cell lung cancer (NSCLC), bone metastases develop during the…
Doc. Debora Karetová: Do Not Underestimate the Complexity of CHVO Treatment and Early Stages of the Disease
Are you applying the optimal approach to the treatment of chronic venous disease? What do the new…
Brigatinib in Patients with ALK+ NSCLC – Final Results of the J-ALTA Clinical Study
At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early…
Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib
Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect…
Current Findings on Progressive Fibrosis in Interstitial Lung Disease
Leading pulmonologists around the world recently published the first of a series of three review…
Risks Associated with Higher Residual Concentrations of Dabigatran in Seniors and Their Prevalence
Dabigatran is a direct thrombin inhibitor indicated for patients across the age spectrum. The…
Current Treatment Options for Refractory/Relapsed CLL
How have treatment protocols for chronic lymphocytic leukemia changed in recent years? A review…
New ESMO Recommendations for Investigating Circulating Tumor DNA
Liquid biopsy has been discussed in oncology for several decades. As we move from conference…
Comparison of Biologics in the Treatment of Chronic Rhinosinusitis with Nasal Polyps
The authors of a meta-analysis of nine randomized controlled trials comparing dupilumab,…